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avoid stroke with anticoagulation; B, better symp‑
tom management with rate or rhythm control; C, 
cardiovascular and comorbidity risk management) 
INTRODUCTION The Atrial fibrillation Better Care 
(ABC) pathway for holistic management, intro‑
duced in 2017, provides a useful approach (A, 
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ABSTRACT
INTRODUCTION The Atrial fibrillation Better Care (ABC) pathway provides a useful way of simplifying 
decision ‑making considerations in a holistic approach to atrial fibrillation management.
OBJECTIVES To evaluate adherence to the ABC pathway and to determine major gaps in adherence in 
patients in the BALKAN ‑AF survey.
PATIENTS AND METHODS In this ancillary analysis, patients from the BALKAN ‑AF survey were divided 
into the following groups: A (avoid stroke) + B (better symptom control) + C (cardiovascular and co‑
morbidity risk management)‑adherent and ‑nonadherent management.
RESULTS Among 2712 enrolled patients, 1013 (43.8%) patients with mean (SD) age of 68.8 (10.2) years 
and mean CHA2DS2 ‑VASc score of 3.4 (1.8) had A+B+C‑adherent management and 1299 (56.2%) had 
A+B+C‑nonadherent management. Independent predictors of increased A+B+C‑adherent manage‑
ment were: capital city (odds ratio [OR], 1.23; 95% CI, 1.03–1.46; P = 0.02), treatment by cardiologist 
(OR, 1.34; 95% CI, 1.08–1.66; P = 0.01), hypertension (OR, 2.2; 95% CI, 1.74–2.77; P <0.001), dia‑
betes mellitus (OR, 1.28; 95% CI, 1.05–1.57; P = 0.01), and multimorbidity (the presence of 2 or more 
long ‑term conditions) (OR, 1.85; 95% CI, 1.43–2.38; P <0.001). Independent predictors of decreased 
A+B+C‑adherent management were: age 80 years or older (OR, 0.61; 95% CI, 0.48–0.76; P <0.001) 
and history of bleeding (OR, 0.5; 95% CI, 0.33–0.75; P = 0.001).
CONCLUSIONS Physicians’ adherence to integrated AF management based on the ABC pathway was suboptimal. 
Addressing the identified clinical and system ‑related factors associated with A+B+C‑nonadherent manage‑
ment using targeted approaches is needed to optimize treatment of patients with AF in the Balkan region.
EDITORIAL
by Pignatelli, Violi, 
Pastori, see p. 176
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collect real ‑world data concerning consecutive 
patients with nonvalvular AF documented on 
electrocardiography. Patients managed in hos‑
pitals and outpatient settings were included, ir‑
respective of whether AF was the main reason 
for the visit or stay in the hospital. Patients were 
assessed by a cardiologist or an internal medi‑
cine specialist if a cardiologist was not available. 
Participating countries were: Albania, Bosnia 
and Herzegovina, Bulgaria, Croatia, Montene‑
gro, Romania, and Serbia (a total of more than 
50 million inhabitants). Each country recruited 
university and nonuniversity hospitals and out‑
patient health centers located in different cities 
or rural areas.
This 14 ‑week (performed from December 
2014 to February 2015), multicenter (a total 
of 49 centers), observational survey was creat‑
ed and conducted by the Serbian Atrial Fibrilla‑
tion Association. The snapshot registry was in‑
troduced to the national cardiology societies or 
relevant working groups in certain Balkan coun‑
tries. The respective national coordinator select‑
ed the centers which precisely reflected AF man‑
agement in a particular country in daily clinical 
practice. In participating countries, the registry 
was approved by the national and / or local in‑
stitutional review board. An informed consent 
form was collected from the patients before en‑
rolment. The study protocol is consistent with 
the ethical guidelines of the 1975 Declaration 
of Helsinki.
Patients with prosthetic mechanical heart 
valves, moderate or severe mitral valve stenosis, 
or any significant heart valve disease with indi‑
cations for surgical treatment and those young‑
er than 18 years were not included in the study.
Data were collected using an electronic case 
report form, and the following information was 
acquired: patients’ clinical characteristics and 
AF ‑related characteristics, healthcare facility 
type and location, patients’ physical findings 
and management at the enrollment visit and fur‑
ther management after discharge. All cardiovas‑
cular risk factors, diseases, and risk scores were 
defined according to individual European Soci‑
ety of Cardiology guidelines, other guidelines, 
scientific statements and textbooks present‑
ed previously in supplementary information.7 
Stroke risk was evaluated using the CHA2DS2‑
‑VASc score.8 Bleeding risk was evaluated us‑
ing the HAS ‑BLED (hypertension, abnormal re‑
nal / liver function, stroke, bleeding history or 
predisposition, labile international normalized 
ratio [INR], elderly [>65 years], drugs or alcohol 
concomitantly) score.8
There was no regular monitoring of centers and 
follow ‑up visits. Consecutiveness of enrolled pa‑
tients, correctness and completeness of data were 
confirmed by the national coordinators and all 
investigators.
In this ancillary analysis, patients were divid‑
ed into A+B+C ‑adherent and A+B+C‑nonadher‑
ent management groups.
that simplifies decision ‑making considerations, 
especially in busy clinics and ward settings.1 The A 
component of the ABC pathway includes identi‑
fying patients with low risk of stroke based on 
the CHA2DS2 ‑VASc (congestive heart failure [HF], 
hypertension, age 75 years or older, diabetes, 
stroke / transient ischemic attack, vascular dis‑
ease, age 65 to 74 years, sex category) score. In‑
dividuals with 1 or more risk factors for stroke 
should be offered stroke prevention (either a vi‑
tamin K antagonist with a well ‑managed time 
in therapeutic range or a non–vitamin K antag‑
onist oral anticoagulant). The B component fo‑
cuses on optimizing symptoms of atrial fibril‑
lation with rate or rhythm control. The C com‑
ponent is to address comorbidities or concom‑
itant risk factors, like hypertension, HF, diabe‑
tes mellitus, cardiac ischaemia, and sleep apnea, 
including lifestyle changes (such as lowering ex‑
cessive body weight, regular physical activity, and 
reducing alcohol and stimulant use). Patients’ 
values and preferences should be considered.1 
The idea of integrated care has been popularized 
to improve patient outcomes.2 Compliance with 
the ABC pathway has been associated with a de‑
creased rate of cardiovascular events3,4 and sig‑
nificantly lower healthcare costs5 compared with 
noncompliance with the ABC approach.
Given the evident benefits of the ABC path‑
way, there is a need for systematic collection of 
real ‑world data concerning adherence to inte‑
grated management of patients with atrial fibril‑
lation (AF), since registry ‑based data may enable 
the identification of barriers for evidence ‑based 
treatment of AF patients in clinical practice. Con‑
temporary registries provide useful insights into 
prevailing clinical patterns of AF management 
among physicians across Europe. However, coun‑
tries in the Balkan region were largely under‑
‑represented in recent registries and data regard‑
ing management of patients with AF in most of 
these countries are scarce.
The aim of this study was to investigate ad‑
herence to the ABC holistic approach and deter‑
mine major gaps in adherence to the ABC pathway 
among participants of the BALKAN ‑AF survey.
PATIENTS AND METHODS An outline of the 
BALKAN ‑AF survey has been previously pub‑
lished.6 This survey was created to prospectively 
WHAT’S NEW?
Countries in the Balkan region were largely underrepresented in recent registries 
on atrial fibrillation. Our study evaluated adherence to the Atrial fibrillation Better 
Care (ABC) holistic approach and determine major gaps in adherence to the ABC 
pathway among participants of the BALKAN ‑AF survey. Physicians’ adherence 
to integrated atrial fibrillation management based on the ABC pathway was 
suboptimal in our study. Multivariable predictors of A+B+C‑nonadherent man‑
agement were age 80 years or older and a history of bleeding, whilst capital city, 
treatment by cardiologist, hypertension, diabetes mellitus, and multimorbidity 
were independently associated with A+B+C ‑adherent management.
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(P = 0.004), anemia (P <0.001), or prior bleed‑
ing events (P = 0.03). Patient characteristics are 
shown in TABLE 1.
Stroke and bleeding risk profile The mean CHA2DS2‑
‑VASc (P = 0.41) and HAS ‑BLED score (P = 0.31) 
values were similar in both groups (TABLE 2). Pa‑
tients with A+B+C ‑adherent management had 
lower prevalence of a CHA2DS2 ‑VASc score of 0 
(P <0.001) and a CHA2DS2 ‑VASc score of 0 in men 
or 1 in women (P <0.001), and were more like‑
ly to have a CHA2DS2 ‑VASc score of 2 or higher 
(P = 0.01) (TABLE 2).
Stroke prevention strategies Patients in the A+B+C‑
‑adherent management group were more like‑
ly to receive OAC overall (P <0.001), OAC alone 
(P <0.001), NOAC (P <0.001), VKA (P <0.001), 
dual antithrombotic therapy (P <0.001), or tri‑
ple antithrombotic therapy (P <0.001), and less 
likely to have single antiplatelet therapy (SAPT) 
alone (P <0.001), dual antiplatelet therapy (DAPT) 
alone (P <0.001), or no antithrombotic therapy 
(P <0.001) (TABLE 2).
Patients with A+B+C ‑adherent manage‑
ment were more likely to receive acenocouma‑
rol (P <0.001), warfarin (P <0.001), dabigatran 
(P <0.001), rivaroxaban (P <0.001), and apix‑
aban (P <0.001) (TABLE 2). Only one patient had 
a history of percutaneous left atrial append‑
age closure.
Adherence to recommendations on stroke prevention 
from the ABC pathway Data on A ‑adherent man‑
agement were available for 2671 patients (98.5%). 
Among patients with a CHA2DS2 ‑VASc score of 
0 (men) or 1 (women), 70 (53.0%) received OAC 
alone, 12 (9.2%) used SAPT alone, 1 (0.7%) used 
DAPT alone, 5 (3.8%) used dual antithrombotic 
therapy, and 44 (33.3%) received no antithrom‑
botic therapy (Supplementary material, Table S1).
Among patients with high stroke risk 
(CHA2DS2 ‑VASc score ≥2), 1048 (59.9%) received 
OAC alone, 214 (12.2%) used SAPT alone, 88 
(5.0%) used DAPT alone, 190 (10.9%) received 
dual antithrombotic therapy, 68 (3.5%) used tri‑
ple antithrombotic therapy, and 143 (8.5%) had 
no antithrombotic therapy (Supplementary ma‑
terial, Figure S1).
HAS ‑BLED score strata are presented in 
the Supplementary material, Figure S2. Among 
patients with HAS ‑BLED score of less than 3, 
98 (7.4%) received dual antithrombotic thera‑
py, whilst of those with HAS ‑BLED score of 3 or 
higher, 80 (12.7%) were treated with dual anti‑
thrombotic therapy.
The mean (SD) most recent INR was 2.42 (1) 
in patients on VKA, and in 522 patients (55.2%) 
the INR value was within therapeutic range (from 
2 to 3).
Adherence to the ABC recommendations on better 
symptom management Among 2106 symptomat‑
ic patients (defined as having an EHRA symptom 
A ‑adherent management was defined as the use 
of oral anticoagulants (OAC) in patients with AF 
with a CHA2DS2 ‑VASc score of 1 or more (men) 
or 2 or more (women), or no OAC in those with 
a CHA2DS2 ‑VASc score of 0 (men) or 1 (women).
A ‑nonadherent management was defined as 
concomitant use of antiplatelet therapy without 
clinical indications, or no OAC use in patients 
with indications for OAC therapy.
B ‑adherent management was classified as rate 
or rhythm control strategy in patients with Euro‑
pean Heart Rhythm Association (EHRA) symp‑
tom score of 2 or more. Patients with EHRA 
symptom score less than 2 were not included in 
the B ‑adherent management group.
B ‑non adherent management was neither rate 
nor rhythm control in patients with EHRA symp‑
tom score of 2 or higher. Patients with EHRA 
symptom score of less than 2 were not included 
in the B ‑nonadherent management group.
C ‑adherent management was defined as the use 
of concomitant disease ‑specific treatment(s) ac‑
cording to current guidelines or no management 
in case of no comorbidities.9-12
C ‑nonadherent management was defined as 
the lack of use of concomitant disease ‑specific 
treatment according to current guidelines.
Statistical analysis Categorical variables were ex‑
pressed as absolute frequencies and percentages, 
and continuous variables as mean (SD). Categorical 
variables with normal distribution were compared 
with the t test. Continuous variables with skewed 
distribution were compared with the Mann–Whit‑
ney test. The descriptive analysis involved baseline 
characteristics of A+B+C ‑adherent and ‑nonadherent 
patients. Comparative analyses among patients with 
A, B, C, A+B, or A+B+C ‑adherent management were 
performed using univariate and multivariate logistic 
regression analyses. Statistically significant variables 
on univariate logistic regression model were entered 
into multivariate logistic regression model to identify 
multivariable predictors of A, B, C, A+B, and A+B+C‑
‑adherent management. Results are showed as odds 
ratio (OR) with 95% CI. A 2 ‑sided P value of less than 
0.05 was interpreted as significant. All analyses were 
performed using the SAS software, version 9.4 (SAS 
Institute Inc., Cary, North Carolina, United States).
RESULTS Patient characteristics In this analy‑
sis, 2712 patients were enrolled at 49 centers in 
7 countries. Complete data on A+B+C ‑adherent 
or ‑nonadherent management were available 
in 2312 patients (85.3%). Patients in the ABC‑
‑adherent management group were more like‑
ly to be women (P = 0.02) and more frequently 
had hypertension (P <0.001), diabetes mellitus 
(DM) (P = 0.01), history of percutaneous coro‑
nary intervention / stenting (P = 0.01), thyroid 
disease (P = 0.04), and multimorbidity (defined as 
the presence of 2 or more long ‑term conditions)13 
(P = 0.001). They were less likely to have paroxys‑
mal AF (P = 0.04), asymptomatic AF (P <0.001), 
HF (P <0.001), history of myocardial infarction 
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TABLE 1 Patient clinical characteristics according to adherence to the Atrial fibrillation Better Care pathway
Variable ABC‑nonadherent 
(n = 1299)
ABC‑adherent 
(n = 1013)
P value
Age, y Mean (SD) 69.7 (11.6) 68.8 (10.2) 0.06
Range 21–96 18–95 –
Female sex 557 (42.9) 485 (47.9) 0.02
Alcohol abuse 58 (4.5) 47 (4.6) 0.84
Paroxysmal AF 494 (38) 344 (34) 0.04
Persistent AF 157 (12.1) 151 (14.9) 0.14
Permanent AF 550 (42.3) 392 (38.7) 0.08
AF history <1 year 180 (13.9) 144 (14.2) 0.97
AF history >5 years 255 (19.6) 205 (20.2) 0.99
Asymptomatic AF currently 206 (15.9) 0 (0) <0.001
Symptomatic AF currentlya 1093 (84.1) 1013 (100) <0.001
EHRA symptom score, %, mean (SD) 2.2 (0.8) 2.5 (0.6) <0.001
Heart rate, bpm, mean (SD) 92.3 (29.3) 94.0 (28.9) 0.17
Systolic BP, mm Hg, mean (SD) 132.2 (23) 136.8 (21.4) <0.001
Diastolic BP, mm Hg, mean (SD) 79.6 (12.3) 82.1 (12.4) <0.001
First diagnosed AF 348 (26.8) 251 (24.8) 0.27
Lone AF 36 (2.8) 17 (1.7) 0.08
Concomitant diseases
Prior or current HF 684 (52.7) 413 (40.8) <0.001
DCM 113 (8.7) 84 (8.3) 0.73
Symptoms of HF currently 657 (50.6) 415 (41) <0.001
Hypertension 882 (67.9) 898 (88.6) <0.001
CAD 435 (33.5) 306 (30.2) 0.09
Prior MI 220 (17) 122 (12) 0.004
History of PCI / stenting 100 (7.7) 95 (9.4) 0.01
Mitral valve regurgitation 456 (35.1) 315 (31.1) 0.04
Aortic valve disease 173 (13.3) 112 (11.1) 0.10
PAD 56 (4.3) 47 (4.6) 0.71
Thyroid disease 120 (9.2) 121 (11.9) 0.04
Diabetes mellitus 302 (23.2) 287 (28.3) 0.01
Anemia 238 (18.3) 113 (11.1) <0.001
CKD 227 (17.5) 153 (15.1) 0.13
COPD 197 (15.2) 125 (12.3) 0.049
Sleep apnea 21 (1.6) 28 (2.8) 0.06
Dementia 45 (3.5) 21 (2.1) 0.045
Malignancy 57 (4.4) 46 (4.5) 0.88
Liver disease 61 (4.7) 29 (2.9) 0.02
Prior stroke 142 (10.9) 100 (9.9) 0.40
Prior TIA 35 (2.7) 38 (3.8) 0.15
Prior SE 10 (0.8) 8 (0.8) 0.96
Prior bleeding 72 (5.5) 37 (3.7) 0.03
Obesity 328 (25.3) 250 (24.7) 0.83
Multimorbidityb 1063 (81.8) 921 (90.9) <0.001
Data are presented as number (percentage) of patients unless otherwise indicated.
a EHRA symptom score ≥2
b The presence of 2 or more long ‑term conditions13
Abbreviations: ABC, Atrial fibrillation Better Care; AF, atrial fibrillation; BP, blood pressure; CAD, coronary artery 
disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; 
EHRA, European Heart Rhythm Association; HF, heart failure; MI, myocardial infarction; PAD, peripheral artery disease; 
PCI, percutaneous coronary intervention; SE, systemic embolism; TIA, transient ischemic attack
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prevention strategy, 1991 patients (74.5%) were 
managed by an A ‑adherent strategy, whilst 680 pa‑
tients (25.5%) had an A ‑nonadherent management.
Independent predictors of A ‑adherent man‑
agement were: capital city (OR, 2.27; 95% CI, 
1.87–2.76; P <0.001), treatment by cardiologist 
(OR, 1.34; 95% CI, 1.08–1.67; P = 0.01), hyperten‑
sion (OR, 1.73; 95% CI, 1.40–2.15; P <0.001), dilat‑
ed cardiomyopathy (OR, 1.90; 95% CI, 1.27–2.85; 
P = 0.002), and thyroid disease (OR, 1.49; 95% 
CI, 1.07–2.06; P = 0.002) (Supplementary mate‑
rial, Table S1), whereas age 80 years or older (OR, 
0.49; 95% CI, 0.41–0.63; P <0.001), paroxysmal 
AF (OR, 0.47; 95% CI, 0.39–0.57; P <0.001), and 
CAD (OR, 0.76; 95% CI, 0.63–0.92; P = 0.01) were 
independently associated with a lower likelihood 
of A ‑adherent management (Supplementary ma‑
terial, Table S1).
B -adherent management Among 2106 symptomat‑
ic patients (an EHRA symptom score of ≥2), 1899 
(90.2%) received B ‑adherent management, where‑
as 207 (9.8%) received B ‑nonadherent treatment.
Independent predictors of lower likelihood 
of B ‑adherent management were: paroxysmal 
AF (OR, 0.68; 95% CI, 0.5–0.9; P = 0.01) and AF 
history of less than 1 year (OR, 0.64; 95% CI, 
0.42–0.98; P = 0.04) (Supplementary materi‑
al, Table S1).
C -adherent management Among 2702 patients 
(99.6%) with available data on C ‑adherent man‑
agement, 1951 patients (72.2%) received C ‑ad‑
herent management, whilst 751 patients (27.8%) 
had C ‑non adherent management. Indepen‑
dent predictors of C ‑adherent management 
were: capital city (OR, 1.37; 95% CI, 1.14–1.64; 
P = 0.001), nonemergency center (OR, 2.14; 95% 
CI, 1.74–2.63; P <0.001), paroxysmal AF (OR, 1.35; 
95% CI, 1.08–1.70; P = 0.01), first ‑diagnosed AF 
(OR, 1.51; 95% CI, 1.22–1.88; P <0.001), hyper‑
tension (OR, 8.96; 95% CI, 7.05–11.38; P <0.001), 
DM (OR, 1.86; 95% CI, 1.49–2.31, P <0.001), and 
prior TIA (OR, 2.18; 95% CI, 1.17–4.08; P = 0.01), 
whilst age 80 years or older (OR, 0.69; 95% CI, 
0.55–0.86; P = 0.002), HF (OR, 0.15; 95% CI, 
0.12–0.19; P <0.001), chronic kidney disease (OR, 
0.55; 95% CI, 0.44–0.69; P <0.001), and history of 
bleeding (OR, 0.56; 95% CI, 0.38–0.81; P = 0.002) 
were negatively associated with C ‑adherent man‑
agement on multivariable analysis (Supplementa‑
ry material, Table S1).
A+B+C -adherent management Data on A+B+C‑
‑adherent management were available in 2312 
patients (85.3%). Among these, 1013 patients 
(43.8%) had A+B+C ‑adherent management 
and 1299 (56.2%) had A+B+C ‑nonadherent 
management.
Independent predictors of the A+B+C ‑adherent 
management were: capital city (OR, 1.23; 95% CI, 
1.03–1.46; P = 0.02), treatment by cardiologist 
(OR, 1.34; 95% CI, 1.08–1.66; P = 0.07), hyper‑
tension (OR, 2.20; 95% CI, 1.74–2.77; P <0.001), 
score of ≥2), 689 (32.7%) were managed using 
a rhythm control strategy and 1311 (62.3%) un‑
derwent a rate ‑control strategy. Overall, 514 
(24.4%) patients were prescribed amiodarone, 
174 (8.3%) received propafenone, 1544 (73.3%) 
used a β ‑blocker, 91 (4.3%) used verapamil, 563 
(26.7%) used digoxin, and 62 (2.9%) were sched‑
uled for electrical cardioversion. Other medica‑
tions and strategies are listed in TABLE 3.
Adherence to cardiovascular and comorbidity risk man-
agement from the ABC pathway The prevalence and 
management of the most frequent comorbidities 
are specified in TABLE 4. β ‑Blockers were the most 
prevalent agents in the management of coro‑
nary artery disease (CAD), HF, and hypertension. 
Angiotensin ‑converting enzyme inhibitors were 
the second most frequently used drugs for patients 
with CAD and hypertension, and loop diuretics 
were used in 72.3% of patients with HF (TABLE 4).
A -adherent management Among 2671 pa‑
tients (98.5%) with available data on the stroke 
TABLE 2 Stroke and bleeding risk as well as stroke prevention strategies in patients 
according to adherence to the Atrial fibrillation Better Care pathway
Variable ABC‑nonadherent 
(n = 1299)
ABC‑adherent 
(n = 1013)
P value
CHA2DS2 ‑VASc score, mean (SD) 3.4 (1.9) 3.4 (1.8) 0.41
CHA2DS2 ‑VASc score 0 67 (5.1) 15 (1.5) <0.001
CHA2DS2 ‑VASc score 0 (men) or 
1 (women)
100 (7.7) 21 (2.1) <0.001
CHA2DS2 ‑VASc score ≥2 1096 (84.4) 893 (88.2) 0.01
HAS ‑BLED score, mean (SD) 1.94 (1.2) 1.99 (1.2) 0.31
HAS ‑BLED score <3 906 (69.7) 698 (68.9) 0.79
HAS ‑BLED score ≥3 393 (30.3) 315 (31.1) 0.66
Stroke prevention
Overall OAC 594 (45.7) 992 (97.9) <0.001
OAC alone 506 (39) 836 (82.5) <0.001
NOAC 81 (6.2) 191 (18.9) <0.001
Rivaroxaban 25 (1.9) 71 (7) <0.001
Dabigatran 45 (3.5) 90 (8.9) <0.001
Apixaban 11 (0.8) 30 (3) <0.001
VKA 513 (39.5) 821 (81) <0.001
Acenocoumarol 353 (27.1) 541 (53.4) <0.001
Warfarin 160 (12.3) 279 (27.5) <0.001
Single antiplatelet therapy alone 318 (24.5) 0 <0.001
DAPT alone 120 (9.2) 0 <0.001
Dual antithrombotic therapy 69 (5.3) 127 (12.5) <0.001
Triple antithrombotic therapy 19 (1.5) 49 (4.8) <0.001
No antithrombotic therapy 264 (20.3) 21 (2.1) <0.001
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: CHA2DS2 ‑VASc, congestive heart failure, hypertension, age ≥75 years, 
diabetes, stroke / transient ischemic attack, vascular disease, age 65 to 74 years, sex 
category; DAPT, dual antiplatelet therapy; HAS ‑BLED, hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile international normalised ratio, 
elderly (>65 years), drugs or alcohol concomitantly; NOAC, non–vitamin K antagonist 
oral anticoagulants; OAC, oral anticoagulants; VKA, vitamin K antagonists; others, see 
TABLE 1
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AF history of less than 1 year (OR, 0.65; 95% 
CI, 0.40–1.07; P = 0.09) and AF history of over 
5 years (OR, 0.69; 95% CI, 0.43–1.11; P = 0.13) 
were not associated with the A+B+C ‑adherent 
management.
DISCUSSION The main finding of this ancillary 
analysis is that in the participating Balkan coun‑
tries, physicians’ adherence to the ABC pathway 
for holistic management of patients with AF was 
suboptimal, with less than half of patients with 
AF receiving A+B+C ‑adherent management.
Multivariable predictors of A+B+C ‑nonadherent 
management were age of 80 years or older and 
history of bleeding, whilst capital city, treatment 
by cardiologist, hypertension, DM, and multi‑
morbidity were independently associated with 
A+B+C ‑adherent management. The ABC pathway 
simplifies treatment decision ‑making in a holis‑
tic approach to AF management, thus allowing 
a streamlined approach to AF care that can bridge 
primary and secondary care, cardiologist and non‑
cardiologist and improve patient understanding 
(“as easy as ABC”).
Our study highlighted the unmet needs and 
knowledge gaps that should be addressed to im‑
prove the care for patients with AF in the Bal‑
kan countries. Patients aged 75 years or old‑
er have an increased risk for stroke and major 
bleeding, but the effects of OACs are consistent 
in older age strata in comparison with younger 
patients.14 The BAFTA (Birmingham Atrial Fi‑
brillation Treatment of the Aged) study,15 a ran‑
domized controlled trial WASPO (Warfarin Ver‑
sus Aspirin for Stroke Prevention in Octogenar‑
ians with AF),16 and a large nationwide cohort 
study from Taiwan17 support the use of VKAs or 
NOACs in patients with AF aged 75 years or old‑
er. Available data also support the use of rhythm 
or rate ‑control strategy and implementation of 
integrated AF management in elderly patients to 
improve quality of life and to relieve symptoms.8
Bleeding history should not be an excuse to 
withhold OAC therapy. Regular re assessment of 
bleeding risk should be a part of management 
compliant with the ABC pathway.18 Patients with 
high risk of bleeding should receive OAC with 
close monitoring and frequent follow ‑up visits.8 
The net clinical benefit of OAC in these patients 
is evident.19
In our study, multimorbidity was an indepen‑
dent predictor of better A+B‑ and A+B+C ‑adherent 
management. In one study,20 both over‑ and un‑
deruse of OAC were present in patients with mul‑
timorbidity and indications to OAC. Some stud‑
ies have revealed that multimorbidity is signifi‑
cantly more prevalent in patients with AF than in 
those without AF.21 Multimorbidity is also associ‑
ated with worse survival of patients with AF,21,22 
and AF patients with multimorbidity have high‑
er stroke and bleeding risk. The abovementioned 
findings should be related to prioritizing patients 
with AF and multimorbidity for optimal manage‑
ment according to the ABC pathway.
DM (OR, 1.28; 95% CI, 1.05–1.57; P = 0.01), and 
multimorbidity (OR, 1.85; 95% CI, 1.43–2.38; 
P <0.001). Age of 80 years or older (OR, 0.61; 95% 
CI, 0.48–0.76; P <0.001) and history of bleeding 
(OR, 0.50; 95% CI, 0.33–0.75; P = 0.001) were as‑
sociated with lower likelihood of A+B+C ‑adherent 
management.
TABLE 3 Management of symptomatic patients from the BALKAN ‑AF survey
Variable Symptomatic patientsa 
(n = 2106)
Rhythm control 689 (32.7)
Rate control 1311 (62.3)
Current β ‑blocker 1544 (73.3)
Current verapamil 91 (4.3)
Current diltiazem 18 (0.9)
Current digoxin 563 (26.7)
Current propafenone 174 (8.3)
Current flecainide 1 (0.1)
Current sotalol 17 (0.8)
Current dronedarone 2 (0.1)
Current amiodarone 514 (24.4)
ECV currently or in the future 62 (2.9)
AF catheter ablation currently or in the future 47 (2.2)
AF surgery currently or in the future 1 (0.1)
Atrioventricular node ablation currently or in the future 5 (0.2)
Data are presented as number (percentage) of patients.
a EHRA II ‑IV
Abbreviations: ECV, electrical cardioversion; others, see TABLE 1
TABLE 4 Management of the most prevalent comorbidities in the BALKAN ‑AF survey
Variable Hypertension 
(n = 2121)
HF 
(n = 1163)
CAD 
(n = 821)
Diabetes 
mellitus 
(n = 668)
ACEI 1159 (54.6) 508 (43.7) 406 (49.4) NA
AT1 receptor 
antagonist
467 (22) 262 (22.5) 176 (21.4) NA
Calcium channel 
blocker
525 (24.7) NA 19 (2.3) NA
β ‑Blocker 1592 (75) 882 (75.8) 629 (76.6) NA
Thiazide diuretic 562 (26.5) 222 (19.1) NA NA
Spironolactone NA 316 (27.2) NA NA
Eplerenone NA NA NA NA
Loop diuretic NA 839 (72.3) NA NA
Aspirin NA NA 374 (45.5) NA
Statin NA NA 522 (63.6) NA
Other lipid lowering 
agent
NA NA 10 (1.2) NA
Lifestyle modifications NA NA NA 145 (21.7)
Insulin therapy NA NA NA 153 (22.9)
Oral antidiabetic drugs NA NA NA 442 (66.2)
Data are presented as number (percentage) of patients.
Abbreviations: ACEI, angiotensin ‑converting ‑enzyme inhibitor; AT1, angiotensin ‑type ‑1; 
NA, not available; others, see TABLE 1
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Valley Atrial Fibrillation Project,25 nonperma‑
nent AF was also associated with an increased risk 
of OAC undertreatment, similarly to our study 
where paroxysmal AF was associated with de‑
creased adherence to stroke prevention strategy.
Notably, more patients received VKAs than 
NOACs in both management groups (A+B+C ad‑
herent and nonadherent) although NOACs are 
increasingly recommended as first ‑line therapy 
for stroke prevention in AF,8,26 and the quality 
of VKA management was poor. Improved A ‑ad‑
herent management included treatment by car‑
diologist, consistent with another study,27 and 
the prevalent use of VKAs might have been relat‑
ed to the local reimbursement policies.
Similar to another study, CAD was a predictor 
of guideline nonadherence to OAC therapy in our 
study.28 According to guidelines, OAC monotherapy 
is indicated in AF patients with stable CAD without 
acute coronary syndrome (ACS) and / or percutane‑
ous coronary intervention in the last 12 months.8 
Nevertheless, the use of antiplatelet agents alone 
was highly prevalent in our study (17% of patients 
with CHA2DS2 ‑VASc score ≥2). Although antiplate‑
let therapy does not reduce stroke or mortality, it 
increases the bleeding risk and is not recommend‑
ed for the prevention of AF ‑related thromboembo‑
lism,29,30 the use of monotherapy with antiplatelet 
drugs was still high in some European surveys on 
AF management.31-33 The association of CAD with 
decreased likelihood of A ‑adherent management in 
our study may reflect the management of patients 
with stable CAD and AF using both antiplatelet 
therapy and OAC, which is not justified owing to 
increased risk of major bleeding.34-38
Overall, the association of OAC use with indi‑
vidual stroke risk assessed using the CHA2DS2‑
‑VASc score was weak in our study (Supplemen‑
tary material). Indeed, suboptimal skills in inter‑
preting the CHA2DS2 ‑VASc and HAS ‑BLED scores 
by neurologists and general practitioners were 
recently identified in a needs assessment study 
conducted by the European Society of Cardiolo‑
gy / EHRA, and the uncertainty in interpreting 
the HAS ‑BLED score was reported by 32% of par‑
ticipating cardiologists. Moreover, management 
of complex patients was associated with uncer‑
tainty about OAC use.39 The evident problem re‑
garding stroke prevention in patients with AF in 
the BALKAN ‑AF registry was also low ‑quality an‑
ticoagulation (nearly half of the patients on VKA 
had INR not within therapeutic range).
In our study, 62% of symptomatic patients 
received rate ‑control strategy whilst 32% were 
managed using a rhythm ‑control strategy. Both 
strategies are noninferior in relation to mortality, 
stroke, and hospitalization.40 However, rhythm‑
‑control strategy in short term is linked with im‑
provement in symptoms and functional capacity.41 
β ‑Blockers were the most commonly used drugs 
for rate control, whilst amiodarone was most fre‑
quently used for rhythm control. Nonpharma‑
cological methods of rhythm control were less 
commonly used compared with pharmacological 
We observed that the adherence to specific 
components of the integrated approach of AF 
management was relatively high (74% of pa‑
tients with A ‑adherent management, 90% with 
B ‑adherent management, and 72% with C ‑ad‑
herent management). However, the adherence 
to all 3 or at least 2 components of ABC holistic 
approach was still suboptimal. Observed differ‑
ences in the use of the ABC pathway according 
to the physician specialty and health center lo‑
cation (ie, better adherence to the ABC manage‑
ment in sites located in capital cities and when 
treatment was undertaken by a cardiologist) may 
highlight the system ‑related barriers to optimal 
management of AF patients, as well as the knowl‑
edge gaps among physicians managing these pa‑
tients in daily practice. In one study,23 barriers in 
the implementation of guideline ‑recommended 
AF management specific to physicians and health‑
care system in Poland were assessed. The num‑
ber of significant educational gaps among physi‑
cians from Poland and other European countries 
is low. However, physicians were uncertain about 
the identification and pathophysiological classi‑
fication of AF. They also reported suboptimal col‑
laboration with other specialists.
Paroxysmal AF was an independent predic‑
tor of decreased A‑, B‑, and A+B ‑adherent man‑
agement. Available data show that patients with 
paroxysmal AF and conventional stroke risk fac‑
tors should be anticoagulated. In one study, year‑
ly ischemic stroke rates were 2.1% for paroxysmal 
AF and 4.2% for permanent AF.24 Although lower 
than among patients with permanent AF, annual 
stroke rates in patients with paroxysmal AF and 
clinical stroke risk factors are sufficiently high to 
merit OAC use, hence the pattern of AF should 
not affect the decision to use OAC.8 In the Loire 
TABLE 5 Independent predictors of A+B+C ‑adherent management in the Balkan 
region (see also Supplementary material, Table S1)
Variable Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Age ≥80 years 0.61 (0.46–0.74) <0.001 0.61 (0.48–0.76) <0.001
Capital city 1.17 (1.01–1.41) <0.001 1.23 (1.03–1.46) 0.02
University center 1.46 (1.13–1.89) 0.003 1.37 (0.81–1.69) 0.425
Treatment by 
cardiologist
1.31 (1.05–1.59) 0.01 1.34 (1.08–1.66) 0.01
Non emergency 
center
1.31 (1.07–1.60) 0.01 1.39 (0.93–1.69) 0.658
Hypertension 2.16 (1.71–2.72) <0.001 2.2 (1.74–2.77) <0.001
Diabetes mellitus 1.23 (1.00–1.50) 0.04 1.28 (1.05–1.57) 0.01
Bleeding events 0.52 (0.34–0.79) 0.002 0.5 (0.33–0.75) 0.001
Thyroid disease 1.34 (1.02–1.75) 0.03 1.42 (0.88–1.83) 0.14
Multimorbiditya 1.47 (1.13–1.92) 0.004 1.85 (1.43–2.38) <0.001
a The presence of 2 or more long ‑term conditions.13
Abbreviations: A, avoid stroke with anticoagulation; B, better symptom management 
with rate or rhythm control; C, cardiovascular and comorbidity risk management; 
OR, odds ratio
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methods. These findings in our study are consis‑
tent with other reports.42,43
Of note, 72% of patients in our study had their 
concomitant diseases optimally medicated, and 
HF, chronic kidney disease, and bleeding events 
were independently associated with lower likeli‑
hood of C ‑adherent management. Importantly, 
integrated care facilitates optimal management 
of hypertension, HF, DM, CAD, and sleep apnea, 
thus reducing the stroke and cardiovascular risk 
burden.1,44 Interestingly, DM was an independent 
predictor of C‑ and A+B+C ‑adherent management. 
Of note, DM in patients with AF is associated with 
older age, more comorbidities, higher thrombo‑
embolic risk, as well as higher all ‑cause, cardio‑
vascular, and noncardiovascular mortality.45 Fi‑
nally, optimal management of concomitant dis‑
eases should be accompanied by lifestyle modifi‑
cations (obesity reduction, reduction of alcohol 
consumption, regular exercise) and management 
of psychological morbidity, and patient values 
and preferences also need to be considered.2,46
There is evidence that education on AF and an‑
ticoagulation significantly improved adherence 
to warfarin.47 In one study,48 knowledge on AF 
and anticoagulation was compared between pa‑
tients medicated with VKAs and those on NOACs. 
The knowledge on the abovementioned aspects 
was similar. However, patients on NOACs had bet‑
ter knowledge concerning safety issues. Moreover, 
patient’s educational level and socioeconomic sta‑
tus were also associated with better adherence to 
oral anticoagulant therapy in patients with AF.49 
Higher level of education was associated with bet‑
ter patients’ awareness of non–vitamin K oral an‑
ticoagulants.50 Unfortunately, the BALKAN ‑AF 
registry did not assess the knowledge of the pa‑
tients on AF and oral anticoagulation, as well as 
patients’ level of education.
Limitations The  BALKAN ‑AF survey has no 
follow ‑up data to evaluate outcomes. Data re‑
garding patient / prescriber treatment preferenc‑
es are lacking. Information on lifestyle modifica‑
tions is available only in patients with DM and AF, 
while data on eplerenone use in patients with AF 
and HF were lacking. Future prospective studies 
are needed to complement our results.
Conclusions Physicians’ adherence to integrated 
AF management based on the ABC pathway was 
suboptimal in our study. Addressing the identified 
clinical or system ‑related factors associated with 
A+B+C‑nonadherent management using target‑
ed approaches is needed to optimize treatment 
of patients with AF in the Balkan region.
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